We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Target lesion failure and device thrombosis were more ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At 2 years after implantation, a fully bioresorbable ...

At 2 years, there are no significant differences with regard to clinical outcomes between the Absorb everolimus-eluting bioresorbable scaffold and the Xience everolimus-eluting stent, according to ...

The use of bioabsorbable vascular scaffolds (BVS) in patients with critical limb-threatening ischemia (CLTI) results in durable patency out to 24 months, with a high rate of freedom from major ...

WASHINGTON, DC — Patients who received the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) in the ABSORB-3 trial showed a primary outcome, counting only events occurring between the ...